These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33613729)

  • 41. Protein degradation by the ubiquitin-proteasome pathway and organ fibrosis.
    Fukasawa H; Fujigaki Y; Yamamoto T; Hishida A; Kitagawa M
    Curr Med Chem; 2012; 19(6):893-900. PubMed ID: 22229415
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined itraconazole-pentoxifylline treatment promptly reduces lung fibrosis induced by chronic pulmonary paracoccidioidomycosis in mice.
    Naranjo TW; Lopera DE; Diaz-Granados LR; Duque JJ; Restrepo AM; Cano LE
    Pulm Pharmacol Ther; 2011 Feb; 24(1):81-91. PubMed ID: 20851204
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-fibrotic treatments: A review of clinical evidence.
    Allinovi M; De Chiara L; Angelotti ML; Becherucci F; Romagnani P
    Matrix Biol; 2018 Aug; 68-69():333-354. PubMed ID: 29654884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting metabolic dysregulation for fibrosis therapy.
    Zhao X; Kwan JYY; Yip K; Liu PP; Liu FF
    Nat Rev Drug Discov; 2020 Jan; 19(1):57-75. PubMed ID: 31548636
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Soluble Guanylate Cyclase: A New Therapeutic Target for Fibrotic Diseases.
    Hu L; Wang Z; Yi R; Yi H; Xiao S; Chen Z; Hu G; Li Q
    Curr Med Chem; 2017; 24(29):3203-3215. PubMed ID: 28486921
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liver fibrosis: from the bench to clinical targets.
    Pinzani M; Rombouts K
    Dig Liver Dis; 2004 Apr; 36(4):231-42. PubMed ID: 15115333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cu-Zn super oxide dismutase as a potential antifibrotic drug for hepatitis C related fibrosis.
    Emerit J; Samuel D; Pavio N
    Biomed Pharmacother; 2006 Jan; 60(1):1-4. PubMed ID: 16297593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis.
    Murtha LA; Schuliga MJ; Mabotuwana NS; Hardy SA; Waters DW; Burgess JK; Knight DA; Boyle AJ
    Front Physiol; 2017; 8():777. PubMed ID: 29075197
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short-term dexamethasone treatment transiently, but not permanently, attenuates fibrosis after acute-to-chronic kidney injury.
    Moonen L; Geryl H; D'Haese PC; Vervaet BA
    BMC Nephrol; 2018 Dec; 19(1):343. PubMed ID: 30509215
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry.
    Holtze CH; Freiheit EA; Limb SL; Stauffer JL; Raimundo K; Pan WT; Flaherty KR; Kim HJ
    Respir Res; 2020 Feb; 21(1):48. PubMed ID: 32041621
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The emerging roles of β-arrestins in fibrotic diseases.
    Gu YJ; Sun WY; Zhang S; Wu JJ; Wei W
    Acta Pharmacol Sin; 2015 Nov; 36(11):1277-87. PubMed ID: 26388156
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Are we any closer to treating liver fibrosis (and if no, why not)?
    Feng R; Yuan X; Shao C; Ding H; Liebe R; Weng HL
    J Dig Dis; 2018 Mar; 19(3):118-126. PubMed ID: 29389083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adiponectin as a novel biomarker for liver fibrosis.
    Udomsinprasert W; Honsawek S; Poovorawan Y
    World J Hepatol; 2018 Oct; 10(10):708-718. PubMed ID: 30386464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emerging therapies for liver fibrosis.
    Fowell AJ; Iredale JP
    Dig Dis; 2006; 24(1-2):174-83. PubMed ID: 16699275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-Circulating Liposomal Delivery System Targeting at PDGFR-β Enhances the Therapeutic Effect of IFN-α on Hepatic Fibrosis.
    Li Q; Yu Q; Ju J; You T; Yan Z; Nan X; Zhong J; Zhou JE
    Curr Pharm Des; 2017; 23(20):3034-3046. PubMed ID: 27928957
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An endostatin-derived peptide orally exerts anti-fibrotic activity in a murine pulmonary fibrosis model.
    Nishimoto T; Mlakar L; Takihara T; Feghali-Bostwick C
    Int Immunopharmacol; 2015 Oct; 28(2):1102-5. PubMed ID: 26315492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C.
    Tanwar S; Rhodes F; Srivastava A; Trembling PM; Rosenberg WM
    World J Gastroenterol; 2020 Jan; 26(2):109-133. PubMed ID: 31969775
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases.
    Szabò H; Fiorino G; Spinelli A; Rovida S; Repici A; Malesci AC; Danese S
    Aliment Pharmacol Ther; 2010 Jan; 31(2):189-201. PubMed ID: 19832726
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease.
    Beyer C; Distler JH
    Biochim Biophys Acta; 2013 Jul; 1832(7):897-904. PubMed ID: 22728287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting renal fibrosis: Mechanisms and drug delivery systems.
    Nastase MV; Zeng-Brouwers J; Wygrecka M; Schaefer L
    Adv Drug Deliv Rev; 2018 Apr; 129():295-307. PubMed ID: 29288033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.